Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone for the Prevention of Relapse in Schizophrenia
NCT04959032Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Lumateperone 42 mg with Placebo (2 arms). Primary endpoint: Time to First Symptom Relapse at 26 weeks. Started Jul 2021; status: completed.
02
Drugs
lumateperone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04959032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04959032.